<DOC>
	<DOCNO>NCT00057967</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody alemtuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : This phase II trial study well alemtuzumab work treat patient relapsed refractory advance mycosis fungoides Sézary syndrome .</brief_summary>
	<brief_title>Alemtuzumab Treating Patients With Relapsed Refractory Advanced Mycosis Fungoides Sézary Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient relapse recurrent advanced mycosis fungoides Sézary syndrome treat alemtuzumab . - Determine toxicity drug patient . OUTLINE : Patients receive alemtuzumab IV 2 hour three time per week . Treatment continue 12 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mycosis fungoides Sézary syndrome Stage IBIVB Measurable disease One indicator lesions No prior radiotherapy area measurable disease unless clear disease progression site measurable disease outside area prior radiotherapy Generalized erythrodermia patient evaluable disease allow Must fail least 1 prior systemic therapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR WHO 02 Life expectancy At least 3 month Hematopoietic WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.2 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal Creatinine great 2.0 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No acute infection require intravenous antibiotic No prior neoplasm except treat squamous cell basal cell skin cancer , treat carcinoma situ cervix , cancer receive surgical treatment patient disease free least 5 year PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior biologic therapy Chemotherapy More 4 week since prior chemotherapy Endocrine therapy More 4 week since prior topical steroid Radiotherapy See Disease Characteristics At least 2 week since prior radiotherapy ( local control palliative ) No concurrent radiotherapy lesion Surgery Recovered prior major surgery Other Recovered prior therapy No concurrent proven investigational antineoplastic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>